Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?

Purpose: To determine an appropriate Risk of Malignancy Index (RMI) cutoff value by comparative analysisof the four malignancy risk indices for distinguishing between borderline ovarian tumor (BOT) and ovarian cancer (OC). Materials and Methods: Retrospective analysis of the medical records of 339 patients (115 BOTsand 224 OCs). Results: There were no significant differences in the area under the ROC curve (AUC) for RMI 1, RMI 2, RMI 3, and RMI 4 (0.792, 0.791, 0.785, and 0.785, respectively). However, the diagnostic capability of the RMI was significantly greater than that of other factors. Conclusion: This study is the first to investigate the performance of the four Risk of Malignancy Indices for distinguishing between BOT and invasive OC. Although there were no significant differences between RMI scores, the RMIs were very effective at predicting an accurate preoperative diagnosis in patients with all BOT and OC histotypes.

Risk of Malignancy Index; Preoperative diagnosis; Borderline ovarian tumor; Ovarian cancer

[1] Vernooij F., Heintz A.P.M., Witteveen P.O., van der Heiden­van der Loo M., Coebergh J., van der Graaf Y.: ”Specialized care and sur­ vival of ovarian cancer patients in The Netherlands: nationwide co­ hort study”. J. Natl. Cancer Inst., 2008, 100, 399.

[2] Bristow R.E., Chang J., Ziogas A., Randall L.M., Anton­Culver H.: ”High­volume ovarian cancer care: survival impact and disparities in access for advanced­stage disease”. Gynecol. Oncol., 2014, 132, 403.

[3] Verleye L., Vergote I., Van Der Zee A.: ”Patterns of care in surgery for ovarian cancer in Europe”. Eur. J. Surg. Oncol., 2010, 36, 108.

[4] Trillsch F., Mahner S., Ruetzel J., Harter P., Ewald­Riegler N., Jaenicke F., et al.: ”Clinical management of borderline ovarian tu­ mors”. Expert. Rev. Anticancer Ther., 2010, 10, 1115.

[5] Skírnisdóttir I., Garmo H., Wilander E., Holmberg L.: ”Borderline ovarian tumors in Sweden 1960­2005: trends in incidence and age at diagnosis compared to ovarian cancer”. Int. J. Cancer, 2008, 123, 1897.

[6] Sherman M.E., Mink P.J., Curtis R., Cote T.R., Brooks S., Hartge P., et al.: ”Survival among women with borderline ovarian tumors and ovarian carcinoma: A population­based analysis”. Cancer, 2004, 100, 1045.

[7] Daraï E., Fauvet R., Uzan C., Gouy S., Duvillard P., Morice P.: ”Fertility and borderline ovarian tumor: a systematic review of con­ servative management, risk of recurrence and alternative options”. Hum. Reprod. Update., 2012, 19, 151.

[8] Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.: ”A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer”. Br. J. Obstet. Gynaecol., 1990, 97, 922.

[9] Tingulstad S., Hagen B., Skjeldestad F.E., Onsrud M., Kiserud T., Halvorsen T., et al.: ”Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre diagnosis of pelvic masses”. Br. J. Obstet. Gynaecol., 1996, 103, 826.

[10] Tingulstad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K., Onsrud M.: ”The risk­of­malignancy index to evaluate poten­ tial ovarian cancers in local hospitals”. Obstet. Gynecol., 1999, 93, 448.

[11] Yamamoto Y., Yamada R., Oguri H., Maeda N., Fukaya T.: ”Com­ parison of four malignancy risk indices in the preoperative evalu­ ation of patients with pelvic masses”. Eur. J. Obstet. Gynecol. Re­ prod. Biol., 2009, 144, 163.

[12] Enakpene C.A., Omigbodun A.O., Goecke T.W., Odukogbe A., Beckmann M.W.: ”Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index”. J. Obstet. Gynaecol. Res., 2009, 35, 131.

[13] Alanbay İ, Akturk E., Coksuer H., Ercan M., Karaşahin E., Dede M., et al.: ”Comparison of risk of malignancy index (RMI), CA125, CA 19­9, ultrasound score, and menopausal status in borderline ovarian tumor”. Gynecol. Endocrinol., 2012, 28, 478.

[14] Yenen M.C., Alanbay I., Aktürk E., Ercan C.M., Coksuer H., Karaşahin E., et al.: ”Comparison of risk of malignancy indices; RMI 1­4 in borderline ovarian tumor”. Eur. J. Gynaecol. Oncol., 2012, 33, 168.

[15] FIGO Committee on Gynecologic Oncology: ”Current FIGO stag­ ing for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia”. Int. J. Gynecol. Obstet., 2009, 105, 3.

[16] Cadron I., Leunen K., Van Gorp T., Amant F., Neven P., Vergote I.: ”Management of borderline ovarian neoplasms”. J. Clin. Oncol., 2007, 25, 2928.

[17] Camatte S., Morice P., Atallah D., Pautier P., Lhommé C., Haie­ meder C., et al.: ”Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies”. J. Am. Coll. Surg., 2002, 195, 332.

[18] Suprasert P., Khunamornpong S., Phusong A., Settakorn J., Siri­ aungkul S.: ”Accuracy of intra­operative frozen sections in the di­ agnosis of ovarian masses”. Asian. Pac. J. Cancer Prev., 2008, 9, 737.

[19] Dadzan M., Tavassoli F.: ”Accuracy of frozen section in borderline ovarian tumor”. Rev. Clin. Med., 2015, 2, 72.

[20] Togashi K.: ”Ovarian cancer: the clinical role of US, CT, and MRI”. Eur. Radiol., 2003, 13, L87.

[21] Valentin L., Ameye L., Testa A., Lécuru F., Bernard J., Paladini D., et al.: ”Ultrasound characteristics of different types of adnexal ma­ lignancies”. Gynecol. Oncol., 2006, 102, 41.

[22] Exacoustos C., Romanini M., Rinaldo D., Amoroso C., Szabolcs B., Zupi E., et al.: ”Preoperative sonographic features of borderline ovarian tumors”. Ultrasound. Obstet. Gynecol., 2005, 25, 50.

[23] Emoto M., Udo T., Obama H., Eguchi F., Hachisuga T., Kawarabayashi T.: ”The blood flow characteristics in border­ line ovarian tumors based on both color Doppler ultrasound and histopathological analyses”. Gynecol. Oncol., 1998, 70, 351.

[24] Valentin L.: ”Pattern recognition of pelvic masses by grayultrasound imaging: the contribution of Doppler ultrasound”. Ul­ trasound Obstet. Gynecol., 1999, 14, 338.

[25] Fischerova D., Zikan M., Dundr P., Cibula D.: ”Diagnosis, treat­ ment, and follow­up of borderline ovarian tumors”. Oncologist, 2012, 17, 1515.

[26] deSouza N.M., O’Neill R., McIndoe G.A., Dina R., Soutter W.P.: ”Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease”. Am. J. Roentgenol., 2005, 184, 999.

[27] Lalwani N., Shanbhogue A.K., Vikram R., Nagar A., Jagirdar J., Prasad S.R.: ”Current update on borderline ovarian neoplasms”. Am. J. Roentgenol., 2010, 194, 330.

[28] Risum S., Høgdall C., Loft A., Berthelsen A.K., Høgdall E., Ned­ ergaard L., et al.: ”The diagnostic value of PET/CT for primary ovarian cancer­a prospective study”. Gynecol. Oncol., 2007, 105, 145.

[29] Jung D., Choi H., Ju W., Kim S., Choi K.: ”Discordant MRI/FDG­ PET imaging for the diagnosis of borderline ovarian tumors”. Int. J. Gynecol. Cancer, 2008, 18, 637.

[30] Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al.: ”The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass”. Gynecol. Oncol., 2008, 108, 402.

[31] Moore R.G., Jabre­Raughley M., Brown A.K., Robison K.M., Miller M.C., Allard W.J., et al.: ”Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass”. Obstet. Gynecol., 2010, 203, 228.

[32] Van Calster B., Van Hoorde K., Valentin L., Testa A.C., Fischerova D., Van Holsbeke C., et al.: ”Evaluating the risk of ovarian can­ cer before surgery using the ADNEX model to differentiate be­ tween benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study”. BMJ, 2014, 349, 5920.